Skip to main content
Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc — Investor Relations & Filings

Ticker · CNTA ISIN · US1523091007 LEI · 213800GIDAARDSKOI827 US Manufacturing
Open in API
Filings indexed 548 across all filing types
Latest filing 2022-08-10 Earnings Release
Country GB United Kingdom
Listing US CNTA

About Centessa Pharmaceuticals plc

https://www.centessa.com/

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that utilizes a Research & Development innovation engine to discover and develop transformational medicines for patients. The company employs a data-driven approach to advance its portfolio of innovative assets. A key program in its pipeline is the development of potential best-in-class, orally administered orexin receptor 2 (OX2R) agonists for the treatment of sleep-wake disorders. Centessa's broader therapeutic focus often includes rare diseases and other areas with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 10, 2022, reporting the announcement of financial results for the quarter ended June 30, 2022. It includes a press release as an exhibit and explicitly states that the information is furnished and not "filed" for certain regulatory purposes. The document is 3775 characters long, which is relatively short and primarily serves to announce the earnings release rather than provide detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). This document fits that description as it announces the quarterly results and includes a press release but does not contain the full financial report or detailed analysis itself.
2022-08-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-04 English
FORM 4 SUBMISSION
Director's Dealing
2022-07-21 English
Regulatory Filings 2022
Regulatory Filings
2022-07-13 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the resignation of a Chief Accounting Officer, appointment of a new principal accounting officer, and approval of restricted stock unit awards to executive officers. These are announcements related to changes in senior management and compensatory arrangements. There are no financial statements or detailed financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). The focus on officer changes and stock awards aligns with Board/Management Information filings. Therefore, the document is best classified as Board/Management Information (MANG).
2022-07-08 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Centessa Pharmaceuticals plc to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references a registration statement filing and requests an effective date for that filing. The document is short (1475 characters) and is a correspondence related to a regulatory filing process, not the filing itself or a financial report. It does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and correspondence that do not fit other categories.
2022-07-08 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.